1 Number of lesions that cleared after first cycle of treatment |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
1.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.2 ALA‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 Recurrence at 12 months |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
2.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Number of lesions that cleared after second treatment cycle |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
3.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.2 ALA‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Number of participants with a good cosmetic outcome (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
4.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5 Number of lesions treated where pain is reported |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
5.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.2 ALA‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Number of adverse events > = 1 in participants |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
6.1 MAL‐PDT versus cryotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |